First five years of life key to preventing obesity, researchers suggest
Experts in the Netherlands found body mass index (BMI) at age six is a better predictor of obesity in later life than at other points of childhood.
They suggest the first years of life are a 'fantastic opportunity to intervene' and give youngsters a 'chance at a happy, healthy' future.
Researchers used data from an ongoing study known as Generation R to track the BMI of thousands of children in the Netherlands at age two, six, 10, 14 and 18.
Of the 3,528 youngsters, some 32.3% were considered overweight or obese at age two, with 22.3% at age six, 24.7% at age 10, and 20.6% at age 14.
Many of these children were still classed as overweight or obese at age 18.
Researchers found every one unit increase in BMI at age six more than doubled a child's odds of being overweight or obese at 18.
They also suggest if a child with a higher BMI reached a healthy weight by the age of six, they were no longer at risk.
Presenting the findings at the European Congress on Obesity in Malaga, Jasmin de Groot, of Erasmus MC, University Medical Centre Rotterdam, said: 'We need to understand how children grow and develop if we are to help future generations grow up healthier and give every child a chance at a happy, healthy life.
'Our research assists with this by showing that a child with overweight or obesity isn't destined to live with overweight or obesity as a young adult – and that the first five years of a child's life provide a fantastic opportunity to intervene and prevent them experiencing overweight and obesity in the years to come.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
14-05-2025
- Scottish Sun
Chocolate biscuits could make you thinner as scientists bid to create sweet treat which works like fat jabs
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) CHOCOLATE biscuits could one day aid weight loss, according to scientists who are inventing snacks to make people feel full. Researchers say antioxidants in the cocoa used to make dark chocolate can trigger fullness hormones. Sign up for Scottish Sun newsletter Sign up 1 Chocolate biscuits could aid weight loss, according to boffins who are inventing snacks to make people feel full Credit: Getty They intensified the effects by creating a special cocoa biscuit then adding a bitter extract from the absinthe plant. A pilot group of 11 people ate the 85g biccie once a day in the morning. Results showed it appeared to stimulate the same hormones as weight-loss jabs, and participants reported being less hungry during the day. The researchers say a feeling of satiety will prevent people from snacking and over-eating. One of the hormones triggered is GLP-1, targeted by anti-fat jabs such as Wegovy and Mounjaro. Study author Dr Flavia Prodam, of the University of Eastern Piedmont in Italy, said: 'All the people who ate the biscuit reported lower hunger before dinner. 'It has already been reported that cocoa and dark chocolate have an effect on satiety and in this biscuit with the bitter compound that effect is even higher. I think the GLP-1 receptor could be affected specifically by the bitter compound but we need to investigate that part.' Dr Prodam and co-author Jessica Baima say their snack is 'very tasty' and would be easy to make commercially. They presented their findings at the European Congress on Obesity and plan to run a clinical trial to test the effect on overweight patients. Dr Prodam added: 'We need to educate people to eat less but there is a lot of failure. The emotional part of eating is important in obesity. People want comfort foods, so having one that decreases hunger could be a good strategy.' It comes after a University of Surrey study this week found that dark chocolate can lower blood pressure.
Scottish Sun
14-05-2025
- Scottish Sun
Scientists finally discover how long it takes before the weight starts piling back on after stopping fat jabs
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) PEOPLE regain the weight they lose on fat jabs within two years of stopping the drugs, research suggests. Ozempic-style injections like Wegovy and Mounjaro are a roaring success due to their rapid slimming effect – but UK rules only allow a maximum two-year prescription. Sign up for Scottish Sun newsletter Sign up 2 People regain the weight they lose on fat jabs within two years, scientists have warned Credit: Getty 2 The experts say people need to start eating healthily and exercising more alongside taking the medication Credit: Getty Many experts believe the drugs need to be taken for much longer. Research by Oxford University has found people typically return to their starting weight one year and eight months after stopping. The analysis, presented at the European Congress on Obesity looked at weight regain in 6,370 people across 11 previous studies. It found those taking Wegovy or Mounjaro regained an average of 1st7lbs (9.6kg) within a year, putting them on track to get back the 2st7lbs (16.1kg) they had lost in less than two years. Those taking older versions of the GLP-1 injections, such as liraglutide, piled the pounds back on even faster, returning to their starting weight in 10 to 11 months. Study author Professor Susan Jebb said: 'These drugs are very effective at helping you lose weight, but when you stop them, weight regain is much faster than diets. 'Either people really have to accept this as a treatment for life or we need to think really hard about how to support people when they stop the drug.' The findings highlight the need for people to start eating healthily and exercising more alongside the medication. NHS rules say that people must be given healthy living advice and monitored during treatment. But the vast majority of people using them to slim down buy them privately, with little to no follow-up from a medic. I've lost 3 stone in 8 months on fat jabs - there's a common error new starters are making & it means nasty side effects Tam Fry, of the National Obesity Forum, said: 'It shouldn't surprise anyone if people regain weight having used GLP-1 drugs without seriously attempting to improve their lifestyle. 'This is not the quick fix which many users believe it to be.' Prof Jane Ogden, of the University of Surrey, added: 'There's no point just throwing people back out into the world to carry on their behaviour from before. 'They're going to need psychological counselling, behaviour change and nutritional support to keep the weight off.'
Reuters
14-05-2025
- Reuters
Health Rounds: Study suggests lower Wegovy dose might be just as effective
May 14 (Reuters) - (To receive the full newsletter in your inbox for free sign up here) The usual dose of Novo Nordisk's ( opens new tab expensive weight-loss drug Wegovy can be cut in half without affecting the results, researchers reported on Tuesday at the European Congress on Obesity in Malaga, Spain. They tracked nearly 2,700 participants in an employer-sponsored weight-loss treatment program who were receiving the GLP-1 drug semaglutide - the main ingredient in Wegovy and Novo's diabetes drug Ozempic. Patients experienced as much weight loss as was seen in earlier clinical trials, but with half the dose, the researchers said. During the 64-week study, participants lost an average of 16.7% of their body weight on a mean dose of just 1.08 milligrams of semaglutide per week, substantially lower than the typical 2.4 mg dose. This was true regardless of body mass index at the start. Nearly 98% of participants lost at least 5% of their starting body weight, a threshold widely recognized as clinically meaningful. Many kept the weight off even after stopping the medication. As GLP-1 use grows and employers' insurance plans need to adapt to the costs, 'the study points to a path toward meaningful outcomes without escalating drug costs,' the researchers said in a statement. Some analysts have forecast sales of newer weight-loss drugs reaching $150 billion a year in the next decade. Embla, the Danish digital weight loss clinic that led the program, uses a treat-to-target protocol that holds doses steady when patients are progressing, with fewer than 30% of users escalating beyond 1 mg per week. 'When care is designed around the patient, lower doses often prove sufficient," Nicholas Syhler, Embla co-CEO, said in a statement. A report of the study, opens new tab by Soren Seier and colleagues at the University of Copenhagen is awaiting peer review. Researchers have identified a potentially crucial component of diabetic nerve pain that could lead to new treatments for the debilitating condition, they reported in Nature Communications, opens new tab. 'Treatment options are not great, and if the underlying diabetes is not managed, people may require amputation due to damage to the peripheral nerves to the point of loss of sensation,' study leader Stephanie Shiers of The University of Texas at Dallas said in a statement. In tissue samples from patients with diabetic neuropathy, the researchers found Nageotte nodules, which are dead sensory nerve cells that have decayed, inside clusters of nerve cells called sensory ganglia. The nodules 'appear to be a sign of degeneration' resulting from damage caused by high blood sugar levels, Shiers said. The finding that Nageotte nodules are a strong indicator of nerve cell death in human sensory ganglia suggests they could become a target for drugs that would protect the nerves or help manage diabetic neuropathy. 'In my view, one of the most important insights we gained from this work is thinking about treating diabetic neuropathic pain differently," senior author Dr. Ted Price of The University of Texas at Dallas said in a statement. "I think what we need to focus on now is neuroprotection at early stages of disease so that these Nageotte nodules do not form in the first place.' BREAST TISSUE TRAITS HELP PREDICT CANCER RISK Women with any of six different breast tissue textures may be at higher risk for breast cancer, researchers reported on Tuesday in Radiology, opens new tab. The researchers used computer algorithms to analyze mammograms of more than 30,000 women without breast cancer, looking for patterns and characteristics that might not be visible to the human eye. They identified six sets of characteristics and then looked at a further set of mammograms from another 3,500 women. The sets of traits, or phenotypes, were associated with a higher risk of invasive breast cancer in both Black and white women -- although it was higher among Black patients -- as well as a higher risk of having a cancer missed on a mammogram or developing a cancer in between scheduled routine mammograms, the researchers said. 'Breast cancer tends to be more aggressive in Black women, highlighting the need for novel risk factors in this population,' co-senior author Despina Kontos of Columbia University Irving Medical Center. In a separate study, researchers at the National Cancer Institute identified a series of changes in the architecture and cell composition of connective tissues of the breast, known as stromal tissue, associated with an increased risk of developing aggressive breast cancer among women with benign breast disease, and poorer rates of survival among women with invasive breast cancer. The changes, which they call stromal disruption, could potentially be used as a biomarker to identify women with noncancerous lumps, cysts, and other changes in breast tissue who are at high risk of developing aggressive breast cancers, as well as those with breast cancer who may be at increased risk of recurrence or death, the researchers said in a report to appear on Wednesday in The Journal of the National Cancer Institute, opens new tab. They used machine learning to detect subtle changes in the stroma of 4,023 donated samples of healthy breast tissue, 974 biopsies of tissue with benign breast disease, and 4,223 biopsies of tissue with invasive breast cancer. (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays)
